Drug intelligence / Profile preview

clobetasol-17-propionate + dithranol

Development stage: Unknown
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

A combination topical therapy consisting of clobetasol-17-propionate (a very potent topical corticosteroid) and dithranol (also known as anthralin). This combination has been shown to enhance the antipsoriatic efficacy of dithranol therapy in terms of clearing capacity and treatment duration, without shortening remission duration. The combination allows for faster clearance of psoriatic lesions and requires lower concentrations of dithranol compared to dithranol monotherapy.

Other names: clobetasol propionate + anthralinclobetasol + anthralin

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on clobetasol-17-propionate + dithranol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clobetasol-17-propionate + dithranol.

Explore the full profile